Dr Daniel Krell

Job title

Consultant medical oncologist

Qualifications

MBChB, BSc, MRCP, DPhil

GMC Number

6075167

Contact details

Email address: danielkrell@nhs.net

PA/secretary phone number: 020 7794 0500 ext 38364/020 8216 4359

PA/secretary email address: kdavis2@nhs.net

Fax: 020 8216 4409

Private practice phone number: 020 7317 2680

Private practice email address: zhowardsmith@theloc.com

Related services

Cancer services, Gastroenterology, Neuroendocrine tumour (NET) unit

Biography

Dr Krell is a consultant medical oncologist at the Royal Free Hospital and Barnet Hospital. He specialises in colorectal, gastro-oesophageal, pancreatic, biliary tract and liver cancer and neuroendocrine tumours. He leads the cancers of unknown primary service at Barnet Hospital. He is actively involved in clinical research and obtained a DPhil in cancer genetics at Oxford University.

Publications

  • Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Krell D, Jeffries S, Khan I, Smith P, Mulholland P. Multi-Centre randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma.  PLOS ONE May 2016.
  • Krell D, Mulholland P, Stebbing J, Tomlinson I, Bardella C. HOT mutation screening in human glioblastoma. Future Science OA, FSO22, DOI: 10.4155/FSO.15.20 (2015).
  • Mulholland P,  Krell D, Khan I, McBain C, Patel C, Wanek K, Hopkins K, Jeffries S, Jager R, Smith P, Liu Q,  Stupp R, Tomlinson I. AT-43* Multi-centre, randomised double-blind phase II study comparing Cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Neuro-oncology 16: V8-22. 2014. Doi:10.1093/neuonc/neu237
  • Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer. 2015 Jul; 51(11):1389-404.
  • Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C. IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013 Dec; 9(12): 1923-35
  • Krell D, Stebbing J. Aristolochia: The Malignant Truth. Lancet Oncol. 2013 Jan;14(1): 25-6
  • Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012 Oct;12(10): 1275-8
  • Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS One. 2011; 6(5): e19868
  • Miller R, Assoku M, Krell D, Sasieni P, Mulholland P. A Retrospective Analysis of Primary Tumour Histology and Survival in Breast Cancer Patients Developing Symptomatic Brain Metastases Treated with Whole Brain Radiotherapy (WBRT) at Mount Vernon Cancer Centre (MVCC). Cancer Research: 2009 Dec; Vol 69, Issue 24, Supplement 3
  • Krell J, Harper-Wynne C, Miles D, Misra V, Cleator S, Krell D, Palmieri C. What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer- A review of the data. J Clin Oncol 27:15s, 2009 (suppl; abstr 1072)
  • Krell D, Jones A. Impact of the effective prevention and management of febrile neutropaenia. Br J Cancer. 2009 Sep;101 Suppl 1:S23-6